Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: CPA-7 influences immune profile and elicits anti-prostate cancer effects by inhibiting activated STAT3

Fig. 2

Therapeutic effects of CPA-7 on RM-9 tumor. a, cell counting assay using in vitro cultured RM-9 cells. ***, P < 0.001 when compared with the vehicle control. b, dynamic curve of tumor sizes during follow-up. The tumor bearing mice were monitored for 30 days, during which tumor sizes were recorded every three days. n = 12 ~ 15 for each group. *, P < 0.05 when compared with the vehicle group. c. Kaplan-Meier plots for overall survival. Tumor bearing mice were treated with CPA-7 at indicated doses or with vehicle and monitored for 30 days. n = 11 ~ 12 for each group. CPA-7 treatment at 1.5 mg/kg significantly prolonged the overall survival of the animals when compared with the vehicle group (*, log-rank P = 0.036). CPA-7 treatment at 0.75 mg/kg also had a trend to prolong the overall survival of the tumor bearing mice (log-rank P = 0.051). d, impact of CPA-7 on median survival time and survival rate at the end of follow-up. Both median survival time (left Y axis) and survival rate (right Y axis) were calculated in the end of the follow-up and plotted to different dose of CPA-7. Each group had 11 ~ 12 mice. *, P < 0.05 when compared with the vehicle group

Back to article page